Lv1
40 积分 2022-09-02 加入
[Expression and Significance of PD-1, PD-L1 and CTLA-4 in the Bone Marrow of Patients with Multiple Myeloma]
17小时前
待确认
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2个月前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
2个月前
已完结
Emerging targets in gastric and pancreatic cancer: Focus on Claudin 18.2
6个月前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
6个月前
已完结
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
7个月前
已完结
Efficacy and safety of recombinant human thrombopoietin for the treatment of chronic primary immune thrombocytopenia in children and adolescents: A multicentre, randomized, double‐blind, placebo‐controlled phase III trial
8个月前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
9个月前
已完结
[Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)]
9个月前
已完结
Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell–engaging bispecific antibody targeting human claudin 6
9个月前
已完结
皖公网安备34019202002308
